Clinical Trials Logo

Stage II Prostate Carcinoma clinical trials

View clinical trials related to Stage II Prostate Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01938339 Recruiting - Clinical trials for Prostate Cancer Recurrent

Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer

Start date: May 2012
Phase: N/A
Study type: Interventional

To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer - to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer - to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer

NCT ID: NCT01792024 Completed - Clinical trials for Stage I Prostate Cancer

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

Start date: January 28, 2013
Phase: N/A
Study type: Interventional

This phase II trial studies how well magnetic resonance (MR)-guided laser interstitial thermal therapy works in treating patients with prostate cancer. Laser therapy uses intense, narrow beams of light to cut and destroy tissue and may help treat prostate cancer

NCT ID: NCT01618838 Terminated - Clinical trials for Stage II Prostate Carcinoma

Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for Prostate Cancer

Start date: February 2011
Phase: N/A
Study type: Interventional

Radiation therapy is a well-established treatment modality for clinically localized prostate cancer. Men who choose to undergo radiation treatments for prostate cancer will have to live with the side effects for many years. Attempts have been made to protect surrounding tissues while delivering high dosage of radiation to cancer. With the rectum being so close to the prostate, many patients still suffer from side effects caused by radiation injury to the rectum, especially those who received conventional external beam radiotherapy. CyberKnife is an FDA approved radiosurgical devise. Its flexible robotic arm allows radiation beams to be delivered in different directions, providing a highly conformal, uniform dose with steep dose gradients. Therefore, treatment with the CyberKnife radiosurgical system should minimize the toxicity to the surrounding structures. CyberKnife System also incorporates a dynamic tracking system to allow the robot to correct the targeting of therapeutic beams during treatment. These improvements allow for dose escalation within the prostate with less normal tissue toxicity. The purpose of this study is to estimate the proportion of patients with endoscopically detectable telangiectasia as the indication of radiation injury to the rectum, after CyberKnife Treatment for prostate cancer.